

**Committee on Energy and Commerce**  
**U.S. House of Representatives**  
 Witness Disclosure Requirement – “Truth in Testimony”  
 Required by House Rule XI, Clause 2(g)(5)

<b>1. Your Name:</b> Michelle Mello		
<b>2. Your Title:</b> Professor of Health Policy and of Law, Stanford University		
<b>3. The Entity(ies) You are Representing:</b> Stanford University School of Medicine, Stanford Law School, and Stanford University’s Institute for Human-Centered Artificial Intelligence.		
<b>4. Are you testifying on behalf of the Federal, or a State or local government entity? (If “Yes,” skip Item 5 and Item 6.)</b>	Yes	No X
<b>5. Grants, Contracts, and Payments</b>  <p style="margin-left: 40px;"><b>a. Please list any <u>Federal grants or contracts</u> that you or the entity(ies) you represent have received <u>on or after January 1, 2023</u>. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.</b></p> <p>I am unable to timely obtain a list of all federal grants and contracts received by Stanford University School of Medicine and Stanford Law School relating to artificial intelligence. If that is needed, I will need to refer you to financial administrators in each of those units of Stanford University.</p> <p style="margin-left: 40px;"><b>b. Please list any <u>contracts or payments originating with a foreign government</u> that you or the entity(ies) you represent have received <u>on or after January 1, 2023</u>. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.</b></p>		
<b>6. Are you a fiduciary (i.e., authorized to act on behalf of or for the benefit of) for any entity that has an interest in the subject matter of the hearing?</b>	Yes	No X
<b>7. Please attach your curriculum vitae to your completed disclosure form.</b>		

Signature: 

Date: 8/28/2025

## CURRICULUM VITAE

**Michelle M. Mello**

Stanford Law School  
559 Nathan Abbott Way, Stanford, CA 94305-8610  
Tel. [REDACTED], Fax [REDACTED]  
Email: [REDACTED]

---

### **EDUCATION:**

2000	Law	J.D.	Yale Law School New Haven, CT
1999	Health Policy and Administration	Ph.D.	University of North Carolina at Chapel Hill, NC
1995	Comparative Social Research	M.Phil.	New College, University of Oxford, Oxford, England
1993	Political Science, Applied Ethics	B.A.	Stanford University, Stanford, CA

### **LICENSURE AND CERTIFICATION:**

2001- Massachusetts State Bar

### **ACADEMIC APPOINTMENTS:**

2021-	Professor of Law, Stanford Law School, and Professor of Health Policy, Department of Health Policy, Stanford University School of Medicine
2019-21	Professor of Law, Stanford Law School, and Professor of Medicine, Center for Health Policy / Primary Care and Outcomes Research, Department of Medicine, Stanford University School of Medicine
2014-19	Professor of Law, Stanford Law School, and Professor of Health Research and Policy, Stanford University School of Medicine
2014-17	Adjunct Professor of Law and Public Health, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health

- 
- 2008-14 Professor of Law and Public Health, Department of Health Policy and Management, Harvard School of Public Health
- 2006-08 C. Boyden Gray Associate Professor of Health Policy and Law, Department of Health Policy and Management, Harvard School of Public Health
- 2005-06 Associate Professor of Health Policy and Law, Department of Health Policy and Management, Harvard School of Public Health
- 2006 Visiting Lecturer, Faculty of Law, University of Otago, Dunedin, New Zealand
- 2000-05 Assistant Professor of Health Policy and Law, Department of Health Policy and Management, Harvard School of Public Health

**ACADEMIC AFFILIATIONS:**

- 2022-23 Faculty Research Fellow, Clayman Institute for Gender Research, Stanford University
- 2021- Institute Faculty, Institute for Human Centered Artificial Intelligence, Stanford University
- 2020- Faculty Affiliate, Freeman Spogli Institute for International Studies, Stanford University
- 2020- Executive Committee, Center for Open and Reproducible Science (CORES), Stanford University
- 2017- Faculty Fellow, Center for Innovation in Global Health, Stanford University
- 2014- Affiliated Faculty, Meta-Research Innovation Center at Stanford (METRICS)
- 2014- Affiliated Faculty, McCoy Family Center for Ethics in Society, Stanford University
- 2014- Core Faculty, Health Policy PhD Program, Stanford University School of Medicine
- 2013-14 Residential Lab Fellow, Edmond J. Safra Center for Ethics, Harvard University
- 2013-14 Faculty Affiliate, Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School

**HONORS AND DISTINCTIONS:**

- 2024 Barbara Allen Babcock Award for Excellence in Teaching, Stanford Law School
- 2022 Ronald C. and Nancy V. Bishop Lecture in Bioethics, University of Michigan.
- 2022 John A. Benson Jr., MD Professionalism Article Prize, ABIM Foundation.
- 2021 Open Science Champion Prize, Center for Open and Reproducible Science (CORES), Stanford University
- 2018 David Barap Brin Visiting Professorship in Medical Ethics, Johns Hopkins University School of Medicine

2017	Dean's Distinguished Scholar in Law, Washington University School of Law
2015	Department of Health Policy and Management Alumni Leadership Award, Gillings School of Public Health, University of North Carolina at Chapel Hill
2013	Elected to National Academy of Medicine (formerly the Institute of Medicine)
2008-13	Robert Wood Johnson Foundation Investigator Award in Health Policy Research
2010	Roger L. Nichols Excellence in Teaching Award, Harvard School of Public Health
2006	Alice S. Hersh New Investigator Award, AcademyHealth
2005-09	Greenwall Faculty Scholar in Bioethics
2005	Citation for Excellence in Teaching, Harvard School of Public Health
2004	Citation for Excellence in Teaching, Harvard School of Public Health
2000	Delta Omega Honorary Public Health Society, Theta Chapter
1997-99	Beinecke Scholar
1995-97	Kenan Fellow, University of North Carolina
1997	Harry T. Phillips Award for Teaching, University of North Carolina
1995	Graduation with Distinction, Oxford University
1993-95	Marshall Scholar
1993	Lyle and Olive Cook Prize, Stanford University
1993	Graduation with Honors and Distinction, Stanford University
1991	Phi Beta Kappa
1990	Cottrell Prize for Political Science, Stanford University

**SELECTED EXTERNAL PROFESSIONAL SERVICE:**

2023	NIH Clinical Center Board of Scientific Counselors
2022-24	Committee on Community Wastewater-based Infectious Disease Surveillance, National Academies of Sciences, Engineering and Medicine
2021-23	Mentor, Emerging Leaders in Health and Medicine Scholars Program, National Academy of Medicine
2020	Report Reviewer, National Academies of Sciences, Medicine and Medicine
2019	Report Review Monitor and Coordinator, National Academies of Sciences, Medicine and Medicine
2016-17	Committee on Ensuring Patient Access to Affordable Drug Therapies, National Academies of Sciences, Engineering and Medicine
2016-	Open Science Expert Panel, Patient-Centered Outcomes Research Institute (PCORI)
2016-17	Committee on Clinical Trials During the 2014-15 Ebola Outbreak, National Academies of Sciences, Engineering, and Medicine

- 2015-24 Advisory Board, McCoy Family Center for Ethics in Society, Stanford University
- 2014-19 Technical Expert Panel, Agency for Healthcare Research and Quality Patient Safety Net (AHRQ PSNet)
- 2014-16 Expert Advisory Group, Patient Safety in Genome Medicine Project (NHGRI ELSI R21 project)
- 2013 Co-Chair, Working Group on Data Sharing, Multi-Regional Clinical Trials Center at Harvard University
- 2010-12 Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs, Institute of Medicine
- 2010-11 Study Section, Research on Research Integrity, NIH / DHHS Office of Research Integrity
- 2009 National Advisory Council Subcommittee on Patient Safety and Medical Liability Reform Demonstrations, Agency for Healthcare Research and Quality
- 2009-11 Board of Directors, Coalition for Health Services Research
- 2008-09 Special Emphasis Panel, Research on Ethical Issues in Human Studies, National Institutes of Health
- 2007-11 Board of Directors, AcademyHealth
- 2007 Bioethics Ad Hoc Study Section, National Institutes of Health
- 2003-06 Links with Academia Advisory Group, American Health Lawyers Association
- 2003 Study Section, National Institute of Neurological Disorders and Stroke
- 2001-04 Ethics Advisory Committee, Children's Hospital, Boston
- 2000-14 Institutional Review Board, Harvard School of Public Health

**PROFESSIONAL SOCIETIES:**

American Society of Law, Medicine and Ethics

**SELECTED OTHER PUBLIC SERVICE:**

- 2023- Committee Member and Volunteer, Young Men's Service League
- 2004-09 Executive Committee, Yale Law School
- 2003-09 Executive Committee, Yale Law School Association of New England
- 2000-08 Volunteer, Boston Cares

**SELECTED ADMINISTRATIVE RESPONSIBILITIES:**

- 2025- Chair, Health Policy Steering Committee, Human Centered Artificial Intelligence Initiative, Stanford University (Member, 2022-2025)

- 2025- Chair, Environmental Health and Safety Committee, Stanford University (Member, 2023-2025)
- 2022-25 Co-Director, Stanford Health Policy Summer Internship Program
- 2022-23 Member, Strategic Planning Committee, Department of Health Policy, Stanford University School of Medicine
- 2021-22 Chair, Appointments Committee, Stanford Law School (Member, 2018-2019)
- 2017 Member, University Long Range Planning Committee, Stanford University
- 2014-17 Member, Committee on Joint Degrees, Stanford Law School
- 2009-15 Key Consultant and Methods Core member, National Program Office, Public Health Law Research Program, Robert Wood Johnson Foundation
- 2015- Member, PhD Program Executive Committee, Stanford Health Policy
- 2009-14 Member, University-wide Committee on Conflicts of Interest, Harvard University
- 2008-14 Member, Committee on Higher Degrees in Health Policy, Harvard University
- 2006-14 Chair, Institutional Review Board, Harvard School of Public Health (Member, 2000-2006)
- 2006-14 Director, Program in Law and Public Health, Harvard School of Public Health (Associate Director, 2001-2006)
- 2000-14 Member, Master of Public Health Steering Committee, Harvard School of Public Health
- 2012-13 Co-chair, Standing Committee on Appointments, Reappointments and Promotions, Harvard School of Public Health (Member, 2011-2012)
- 2006-08 Vice Chair, Faculty Council, Harvard School of Public Health
- 2006-07 Member, Standing Committee on Ethics and Conflict of Interest in Continuing Education, Harvard Medical School

**BUSINESS AND CONSULTING EXPERIENCE:**

- 2024 Expert witness on behalf of health insurers in litigation against Indivior, Inc. relating to Indivior's pharmaceutical marketing practices
- 2023-24 Advisor to AVIA Health, LLC Generative AI Collaborative and AI Collaborative 2.0
- 2022-23 Expert witness on behalf of Humana (health insurer) in litigation against Celgene Corporation relating to Celgene's off-label promotion of prescription drugs
- 2021- Consultant to National Academy for State Health Policy on prescription drug affordability issues
- 2020-24 Expert witness on behalf of pharmacy retailers and health plan in Glumetza antitrust litigation
- 2020-22 Advisor to Verily Life Sciences LLC on product designed to facilitate safe return to work and school during COVID-19

- 2020- Consultant to National Academy for State Health Policy on pharmaceutical price regulation
- 2018-22 Consultant to CVS/Caremark on value-based formulary
- 2015-16 Consultant to the Medicare Payment Advisory Commission (MedPAC) on medical liability issues
- 2014 Consultant to CVS/Caremark on tobacco-free pharmacies
- 2011-12 Consultant to Oregon Health Authority on medical liability reform issues
- 2010-11 Consultant to James Bell Associates, Inc. on evaluation of AHRQ demonstration project program for medical liability and patient safety
- 2009-10 Consultant to the Medicare Payment Advisory Commission (MedPAC) on medical liability reform issues
- 2007-09 Consultant to Common Good on technical assistance to states considering medical liability reform
- 2007-08 Consultant to New York State Medical Liability Task Force
- 2006-07 Consultant to American Cancer Society on study of impact of laws relating to breast cancer screening
- 2006-07 Consultant to American Medical Risk Insurance Company on design of innovative professional liability insurance product
- 2005-06 Consultant to Robert Wood Johnson Foundation Policy Synthesis Project
- 2005 Consultant to Washington State Noneconomic Damages Task Force on study of noneconomic damages schedules
- 2004-05 Consultant to American Hospital Association Task Force on Health Care Liability Reform
- 2004-05 Consultant to Wyoming Health Care Commission on study of medical liability and patient safety reform commissioned by the Wyoming legislature
- 2001 Consultant to plaintiffs' attorneys in *Simon v. Philip Morris Inc.* (consolidated tobacco litigation in the Eastern District of New York).
- 1999 Summer Associate, Perkins Coie LLP, Seattle, WA
- 1999 Summer Associate, Miller, Cassidy, Larroca & Lewin, LLP, Washington, DC
- 1999 Intern, United States Attorney's Office, New Haven, CT
- 1998-99 Intern, New Haven Legal Assistance Association, New Haven, CT

### **JOURNAL ROLES:**

- 2022- Editorial Board, *JAMA Health Forum*
- 2021-25 Editorial Board, *Journal of Health Politics, Policy and Law*
- 2021- Contributing Writer, *JAMA Health Forum*
- 2020- Editorial Advisory Board, *The Milbank Quarterly*
- 2015-2020 Editorial Board, *The Milbank Quarterly*

2012-13	Guest Editor, Theme Issue on Public Health Law Research, <i>Journal of Health Politics, Policy and Law</i>
2005-	Advisory Board on Publication Ethics, <i>PLOS Medicine</i> journal
2004-05	Guest Editor, Symposium Issue on Medical Malpractice, <i>Journal of Law, Medicine &amp; Ethics</i>
1999-00	Essays Chair, <i>Yale Law Journal</i>
1999-00	Editor, <i>Yale Journal of Health Policy, Law, &amp; Ethics</i>
1998-99	Editor, <i>Yale Law Journal</i>
1997-98	Editor, <i>Yale Journal on Regulation</i>

### **MAJOR RESEARCH INTERESTS:**

1. Artificial intelligence
2. Medical malpractice litigation, medical errors, and patient safety
3. Public health law
4. Pharmaceuticals
5. Bioethics

### **RESEARCH SUPPORT:**

#### **PAST FUNDING:**

2022-24	Commonwealth Fund <i>Public Health Powers After COVID-19</i> (Principal Investigator)
2019-23	Greenwall Foundation <i>Ethical and Policy Issues for University Data Sharing in the Age of Big Data</i> (Principal Investigator)
2019-23	Laura and John Arnold Foundation / Johns Hopkins Bloomberg School of Public Health <i>Johns Hopkins Drug Access and Affordability Initiative</i> (Co-investigator)
2022-23	Institute for Human-Centered Artificial Intelligence, Stanford University <i>Tort Liability for Harms Arising from Healthcare AI</i> (Principal Investigator)
2022-23	Institute for Human-Centered Artificial Intelligence, Stanford University <i>Identifying and Communicating Ethical Challenges Bringing AI into Healthcare</i> (Co-investigator)
2020-22	Greenwall Foundation <i>Late Career Practitioners: Balancing Patient Safety and Physician Autonomy</i> (Co-investigator)
2019-22	Arnold Ventures / Bioethics International



- 
- Pharma Integrity Index Project*  
(Co-investigator)
- 2018-19 Stanford University School of Medicine Discovery Innovation Fund  
*Application of Big Data to Medical Malpractice Policy Questions*  
(Principal Investigator)
- 2018-19 California Tobacco Control Program /ChangeLab Solutions  
*Diffusion of Model Ordinances for Local Tobacco Control in California*  
(Co-investigator)
- 2018-19 Laura and John Arnold Foundation / Johns Hopkins Bloomberg School of Public Health  
*Johns Hopkins Drug Access and Affordability Initiative*  
(Co-investigator)
- 2016-19 Alfred P. Sloan Foundation  
*Stanford Data Center for Population and Social Science Research: A Model Data Core*  
(Co-investigator)
- 2016-19 Laura and John Arnold Foundation / Bioethics International  
*Pharma Integrity Index Project*  
(Co-investigator)
- 2016-17 SUMIT Insurance Company Ltd.  
*Practice Changes Among Physicians Who Incur Paid Claims and Disciplinary Actions*  
(Co-investigator)
- 2016-17 Stanford University  
*Cybersecurity and Health Information Exchanges*  
(Co-investigator)
- 2015-16 Greenwall Foundation  
*Clinical Trial Participants' Attitudes Toward Participant-Level Clinical Trial Data Sharing*  
(Principal Investigator)
- 2012-16 Beth Israel Deaconess Medical Center  
*Disclosure, Apology and Offer*  
(Co-investigator)
- 2010-16 National Institutes of Health / DHHS Office of Research Integrity  
*Accountability and the Role of the Principal Investigator in Multicenter Trials*  
(Co-investigator)
- 2010-16 Agency for Healthcare Research and Quality

- 
- New York State Medical Liability Reform and Patient Safety Demonstration Project*  
(Co-investigator)
- 2014-15 Greenwall Foundation  
*Understanding the Lifecycle of Public Opinion of Public Health Laws*  
(Principal Investigator)
- 2013-15 Agency for Healthcare Research and Quality  
*Comprehensive Patient Safety and Medical Liability Communication and Program Resolution Education Toolkit*  
(Co-investigator)
- 2008-14 Robert Wood Johnson Foundation  
*Responding Justly to Patients Harmed by Medical Care: Disclosure, Compensation, and Litigation*  
(Co-Principal Investigator) (Investigator Award)
- 2013-14 Edmond J. Safra Center for Ethics, Harvard University  
*Institutional Oversight of Faculty Consulting Relationships*  
(Residential Lab Fellowship)
- 2010-14 Agency for Healthcare Research and Quality  
*Communication to Prevent and Respond to Medical Injuries: Washington State Collaborative*  
(Co-investigator)
- 2010-13 National Institutes of Health / National Center for Research Resources  
*Restrictive Provisions in Faculty Consulting Agreements*  
(Principal Investigator)
- 2011-13 Greenwall Foundation  
*Moral Legitimacy in Public Health Practice*  
(Principal Investigator)
- 2008-13 National Institutes of Health  
*Harvard Catalyst (Clinical and Translational Science Award)*  
(Co-Investigator, Ethics Core)
- 2010-11 Agency for Healthcare Research and Quality  
*Removing Barriers to Disclosure-and-Offer Models*  
(Co-investigator)
- 2010 Robert Wood Johnson Foundation  
*An Empirical Evaluation of Public Health Law Approaches to Obesity Prevention - Phase II*  
(Principal Investigator)
- 2009-10 Robert Wood Johnson Foundation

- 
- An Empirical Evaluation of Public Health Law Approaches to Obesity Prevention - Phase I*  
(Principal Investigator)
- 2007-10 Robert Wood Johnson Foundation  
*State Policy Approaches to Fostering Uptake of the Human Papillomavirus Vaccine*  
(Principal Investigator)
- 2005-10 Greenwall Faculty Scholars Program  
*Ethical Issues in the Pharmaceutical Industry*  
(Investigator Award)
- 2007-09 Robert Wood Johnson Foundation  
*Preventing Childhood Obesity: Restricting Advertising and Promotion of Foods and Beverages to Children* (Subcontract from Public Health Law & Policy/Yale University)  
(Principal Investigator)
- 2004-08 Robert Wood Johnson Foundation  
*Design of a Reliable System of Medical Justice*  
(Principal Investigator)
- 2003-06 National Institute of Neurological Disorders and Stroke  
*Industry-Sponsored Research Contracts: An Empirical Study of Policies and Practices at Academic Medical Centers (Phase II)*  
(Principal Investigator)
- 2005 Harvard Interfaculty Program for Health Systems Improvement  
*Constitutionality of Administrative Compensation Systems*  
(Co-Principal Investigator)
- 2005 Commonwealth Fund  
*Alternative Approaches to Compensating Medical Injury: Lessons from International Models*  
(Co-investigator)
- 2004-05 Harvard/Kennedy School Health Care Delivery Policy Program  
*Adverse Event Disclosure Evaluation Project Planning Grant*  
(Principal Investigator)
- 2001-05 Agency for Healthcare Research and Quality  
*Malpractice Insurers Medical Error Prevention Study*  
(Co-investigator)
- 2004 US Agency for International Development  
*Health Enhancing Local Partnerships – Local Government Units Project*  
(Co-investigator)

- 2004 Harvard Interfaculty Program for Health Systems Improvement  
*Caps on Noneconomic Damages: Efficacy and Equity*  
(Co-Principal Investigator)
- 2002-04 Pew Charitable Trusts  
*An Empirical Investigation of the Pennsylvania Malpractice Environment* (Principal Investigator)
- 2002-04 National Institute of Neurological Disorders and Stroke  
*Industry-Sponsored Research Contracts: An Empirical Study of Policies and Practices at Academic Medical Centers (Phase I)*  
(Principal Investigator)
- 2002-03 Commonwealth Fund  
*Legal Approaches to Improving the Business Case for Quality*  
(Principal Investigator)
- 2001-02 Harris Interactive/Anderson Consulting  
*Strategic Health Perspectives* (Co-investigator)
- 2001 Harvard Risk Management Foundation  
*Malpractice Insurers Medical Error Prevention Study*  
(Co-investigator)
- 2000-01 National Science Foundation  
*Public Valuation of Lifesaving: The Controllability Issue* (Co-investigator)
- 1998-99 Health Care Financing Administration (Dissertation Grant)  
*Market Penetration, Biased Selection, and Utilization in Medicare HMOs* (Principal Investigator)
- 1996-97 New College, University of Oxford (Thesis Grant)  
*Ethical Issues in "Do-Not-Resuscitate" Decisions*  
(Principal Investigator)

**CURRENT FUNDING:**

- 2024-2027 Stanford Impact Labs  
*Proactive Ethical Assessment of Healthcare AI*  
(Principal Investigator)
- 2024-2027 Patient-Centered Outcomes Research Institute  
*Development of a Scalable Method for Identifying Ethical Issues Arising from Healthcare AI*  
(Co-investigator)
- 2023-2027 NIH

*Identifying Barriers to Optimizing Data Sharing and Accelerate Discovery in Alzheimer's Disease and Related Dementia Research*  
(Co-investigator)

2024-2025 Stanford Health Care  
*FURM Assessments for Healthcare AI Tools*  
(Co-investigator)

**TEACHING EXPERIENCE:**

- 2015- *Torts*. Stanford Law School. Course Director.
- 2015- *Health Law: Improving Public Health*. Stanford Law School and Stanford University School of Medicine. Course Director.
- 2021-24 *Health Policy Graduate Student Tutorial II*. Stanford University School of Medicine. Course Director.
- 2002-14 *Public Health Law*. Harvard School of Public Health. Course Director.
- 2002-14 *Ethical Issues in International Health Research*. Harvard School of Public Health. Member of course faculty.
- 2014 *United States Health Policy*. Harvard School of Public Health / EdX. Member of course faculty.
- 2000-13 *Ethical Basis of the Practice of Public Health: Health Care Delivery*. Harvard School of Public Health. Course Director.
- 2007-08 *Law and Public Health*. Harvard Law School. Course Director.
- 2001-03 *Capstone Course in Law and Public Health*. Harvard School of Public Health. Co-instructor.
- 2000 *Democracy: Conflict, Collective Action, and the State*. Yale University. Teaching Assistant.
- 1997 *Statistical Methods*. University of North Carolina at Chapel Hill. Course Director.
- 1997 *Linear Regression*. University of North Carolina at Chapel Hill. Teaching Assistant.
- 1996 *Health Politics and Policy*. University of North Carolina at Chapel Hill. Teaching Assistant.

**BIBLIOGRAPHY:**

**ARTICLES:**

1. **Mello MM**, Jenkinson C. Comparison of medical and nursing attitudes to resuscitation between a British and an American teaching hospital. *Soc Sci Med* 1998;46:415-24.

2. **Mello MM.** Death, life, and uncertainty: allocating the risk of error in the decision to terminate life support. *Yale Law J* 1999;109:635-42.
3. **Mello MM.** Of swords and shields: the use of clinical practice guidelines in medical malpractice litigation. *Univ Penn Law Rev* 2001;149:645-710.
4. **Mello MM, Brennan TA.** The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer. *Health Aff* 2001;20:101-17.
5. **Mello MM, Brennan TA.** Demystifying the law/science disconnect. *J Health Polit Pol'y Law* 2001;26:429-38.
6. **Mello MM, Stearns SC, Norton EC.** Do Medicare HMOs still reduce health services use after controlling for selection bias? *Health Econ* 2002;11:323-40.
7. **Mello MM.** Policing Medicaid and Medicare managed care: the role of courts and administrative agencies. *J Health Polit Pol'y Law* 2002;27:465-94.
8. **Mello MM, Brennan TA.** Deterrence of medical errors: theory and evidence for malpractice reform. *Texas Law Rev* 2002;80(7):1595-1637.
9. **Mello MM.** Using statistical evidence to prove the malpractice standard of care: bridging legal, clinical, and statistical thinking. *Wake Forest Law Rev* 2002;37:821-59.
10. **Mello MM, Rosenthal M, Neumann PJ.** Direct-to-consumer advertising and shared liability for pharmaceutical manufacturers. *JAMA* 2003;289:477-81.
11. Studdert DM, **Mello MM, Brennan TA.** Medical monitoring for pharmaceutical injuries: tort law for the public's health? *JAMA* 2003;289:889-94.
12. **Mello MM, Studdert DM, Brennan TA.** The Leapfrog standards: ready to jump from marketplace to courtroom? *Health Aff* 2003;22:46-59.
13. Whang E, **Mello MM, Ashley SW, Zinner MJ.** Implementing resident work hour limitations: lessons from the New York experience. *Ann Surg* 2003;237:449-455.
14. Ransom SB, Studdert DM, Dombrowski MP, **Mello MM, Brennan TA.** Reduced medicolegal risk by compliance with obstetric clinical pathways: a case-control study. *Obstet Gynecol* 2003;101:751-755.
15. **Mello MM, Studdert DM, Brennan TA.** The new medical malpractice crisis. *N Engl J Med* 2003;348:2281-84.
16. **Mello MM, Stearns SC, Norton EC, Ricketts TC.** Understanding biased selection in Medicare HMOs. *Health Serv Res* 2003;38:961-92.
17. **Mello MM, Studdert DM, Brennan TA.** The rise of litigation in human subjects research. *Ann Intern Med* 2003;139:40-45.

18. Brennan TA, **Mello MM**. Patient safety and medical malpractice: a case study. *Ann Intern Med* 2003;139:267-273.
19. Burns JP, **Mello MM**, Studdert DM, Puopolo AL, Truog RD, Brennan TA. Results of a controlled clinical trial on care improvement for the critically ill. *Crit Care Med* 2003;31:2107-2117.
20. Studdert DM, Burns JP, **Mello MM**, Puopolo AL, Truog RD, Brennan TA. Nature of conflict in the care of pediatric intensive care patients with prolonged stay. *Pediatrics* 2003;112:553-558.
21. Studdert DM, **Mello MM**, Burns JP, Puopolo AL, Galper BZ, Cook EF, Truog RD, Brennan TA. Conflict in the care of patients with prolonged stay in the ICU: types, sources, and predictors. *Intensive Care Med* 2003;29:1489-1497.
22. **Mello MM**, Brennan TA. Due process in investigations of research misconduct. *N Engl J Med* 2003;349:1280-1286.
23. Whang EE, Perez A, Ito H, **Mello MM**, Ashley SW, Zinner MJ. Work hours reform: perceptions and desires of contemporary surgical residents. *J Am Coll Surg* 2003;197:624-30.
24. **Mello MM**, Kelly CN, Studdert DM, Brennan TA, Sage WM. Hospitals' behavior in a tort crisis: observations from Pennsylvania. *Health Aff* 2003;22:225-233.
25. **Mello MM**, Rimm EB, Studdert DM. The McLawsuit: the fast food industry and legal accountability for obesity. *Health Aff* 2003;22:207-216.
26. **Mello MM**, Burns JP, Truog RD, Studdert DM, Puopolo AL, Brennan TA. Decision making and satisfaction with care in the pediatric ICU: findings from a controlled clinical trial. *Ped Crit Care Med* 2004;5:40-47.
27. Studdert DM, **Mello MM**, Brennan TA. Medical malpractice. *N Engl J Med* 2004;350:283-292.
28. **Mello MM**, Studdert DM, Brennan TA. The pharmaceutical industry versus Medicaid: limits on state initiatives to control prescription drug costs. *N Engl J Med* 2004;350:608-613.
29. **Mello MM**, Hemenway D. Medical malpractice as an epidemiological problem. *Soc Sci Med* 2004;59:39-46.
30. Studdert DM, Yang YT, **Mello MM**. Are damages caps regressive? A study of malpractice jury verdicts in California. *Health Aff* 2004;23:54-67.
31. **Mello MM**, Studdert DM, DesRoches CM, Peugh J, Zapert K, Brennan TA, Sage WM. Caring for patients in a malpractice crisis: physician satisfaction and quality of care. *Health Aff* 2004;23:42-53.

32. Studdert DM, **Mello MM**, Brennan TA. Financial conflicts of interest in physician relationships with the pharmaceutical industry: self-regulation in the shadow of federal prosecution. *New Engl J Med* 2004;351:1891-1900.
33. **Mello MM**. The experience of a community representative on an ethics consult team. *J Clin Ethics* 2004;15:296-301.
34. **Mello MM**, Kelly CN, Brennan TA. Fostering rational regulation of patient safety. *J Health Polit Pol'y Law* 2005;30:375-426.
35. **Mello MM**, Kelly CN. Effects of a professional liability crisis on residents' practice decisions. *Obstet Gynec* 2005;105:1287-1295.
36. **Mello MM**, Clarridge BR, Studdert DM. Academic medical centers' standards for clinical-trial agreements with industry. *N Engl J Med* 2005;352:2202-2210.
37. Studdert DM, **Mello MM**, Sage WM, DesRoches CM, Peugh J, Zapert K, Brennan TA. Defensive medicine among high-risk specialist physicians in a volatile malpractice environment. *JAMA* 2005;293:2609-2617.
38. Entwistle VE, **Mello MM**, Brennan TA. Advising patients about patient safety: current initiatives risk shifting responsibility. *Joint Commission J Qual Patient Safety* 2005;31:483-494.
39. **Mello MM**. Managing malpractice crises. *J Law Med Ethics* 2005;33:414-415.
40. Kelly CN, **Mello MM**. Are medical malpractice damages caps constitutional? An overview of state litigation. *J Law Med & Ethics* 2005;33:515-534.
41. Irani JL, **Mello MM**, Ashley SW, Whang EE, Zinner MJ, Breen E. Surgical residents' perceptions of the effects of the ACGME duty hour requirements one year after implementation. *Surgery* 2005;138:246-253.
42. Breen E, Irani JL, **Mello MM**, Whang EE, Zinner MJ, Ashley SW. The future of surgery: today's residents speak. *Curr Surg* 2005;62:543-546.
43. **Mello MM**, Studdert DM, DesRoches CM, Peugh J, Zapert K, Brennan TA, Sage WM. Effects of the malpractice crisis on specialist supply and access to care. *Ann Surg* 2005;242:621-628.
44. **Mello MM**, Clarridge BR, Studdert DM. Researchers' views of the acceptability of restrictive provisions in clinical trial agreements with industry sponsors. *Accountability in Res* 2005;12:163-191.
45. **Mello MM**, Brennan TA. Legal concerns and the influenza vaccine shortage. *JAMA* 2005;294:1817-1820.



46. **Mello MM**, Powlowski MP, Nañagas JMP, Bossert T. The role of law in public health: the case of family planning in the Philippines. *Soc Sci Med* 2006;63:384-396.
47. Studdert DM, **Mello MM**, Gawande AA, Gandhi TK, Kachalia A, Yoon C, Puopolo AL, Brennan TA. Claims, errors, and compensation payments in medical malpractice litigation. *N Engl J Med* 2006;354:2024-2033.
48. **Mello MM**, Studdert DM, Brennan TA. Obesity--the new frontier of public health law. *N Engl J Med* 2006;354(24):2601-2610.
49. Samanta A, **Mello MM**, Foster C, Tingle J, Samanta J. The role of clinical guidelines in medical negligence litigation: a shift from the *Bolam* standard? *Med Law Rev* 2006;14:321-366.
50. **Mello MM**, Studdert DM, Kachalia A, Brennan TA. "Health courts" and accountability for patient safety. *Milbank Q* 2006;84:459-492.
51. Kesselheim AS, **Mello MM**. Medical process patents—monopolizing the delivery of health care. *N Engl J Med* 2006;355:2036-2041.
52. Studdert DM, **Mello MM**, Gawande AA, Brennan TA, Wang YC. Disclosure of medical injury: an improbable risk management strategy. *Health Aff* 2007;26:215-226.
53. Joffe S, **Mello MM**, Cook EF, Lee SJ. Advance care planning among patients undergoing hematopoietic cell transplantation. *Biol Blood & Marrow Transpl* 2007;13:65-73.
54. Studdert DM, **Mello MM**, Jedrey CM, Brennan TA. Regulatory and judicial oversight of nonprofit hospitals. *N Engl J Med* 2007;356:625-631.
55. Kesselheim AS, **Mello MM**. Confidentiality laws and secrecy in medical research: improving access to data on drug safety. *Health Aff* 2007;26:483-491.
56. **Mello MM**, Studdert DM, Schumi J, Brennan TA, Sage WM. Changes in physician supply and scope of practice during a malpractice crisis: evidence from Pennsylvania. *Health Aff* 2007;26:w425-w435 (web exclusive).
57. Studdert DM, **Mello MM**, Levy MK, Gruen RL, Dunn EJ, Orav EJ, Brennan TA. Geographic variation in informed consent law: two standards for disclosure of treatment risks. *J Empirical Leg Stud* 2007;4:103-124.
58. Brennan TA, **Mello MM**. Sunshine laws and the pharmaceutical industry. *JAMA* 2007;297:1255-1257.
59. **Mello MM**, Joffe S. Compact versus contract: industry sponsors' obligations to their research subjects. *N Engl J Med* 2007;356:2737-2743.

60. **Mello MM**, Studdert DM, Thomas EJ, Yoon C, Brennan TA. Who pays for medical errors? An analysis of adverse event costs, the medical liability system, and incentives for patient safety improvement. *J Empirical Leg Stud* 2007;4(4):835-860.
61. **Mello MM**, Studdert DM, Moran P, Dauer EA. Policy experimentation with administrative compensation for medical injury: issues under state constitutional law. *Harvard J Legis* 2008;45:59-106.
62. **Mello MM**. Rationalizing vaccine injury compensation. *Bioethics* 2008;22(1):32-42.
63. Kachalia AB, Studdert DM, Brennan TA, **Mello MM**. Beyond negligence: avoidability and medical injury compensation. *Soc Sci Med* 2008;66(2):387-402.
64. **Mello MM**. Obesity—personal choice or public health issue? *Nature Clin Pract Endocrinol Metab* 2008;4(1):2-3.
65. Studdert DM, **Mello MM**. When tort resolutions are “wrong”: predictors of discordant outcomes in medical malpractice litigation. *J Leg Stud* 2008;36(Suppl 2):S47-S78.
66. **Mello MM**, Zeiler K. Empirical health law: the state of the field. *Georgetown Law J* 2008;96:649-702.
67. **Mello MM**, Studdert DM. Deconstructing negligence: the role of individual and system factors in causing medical injuries. *Georgetown Law J* 2008;96:599-623.
68. **Mello MM**, Pomeranz J, Moran P. The interplay of public health law and industry self-regulation: the case of sugar-sweetened beverage sales in schools. *Am J Pub Health* 2008;98:595-604.
69. Yang YT, Studdert DS, Subramanian SV, **Mello MM**. A longitudinal analysis of the impact of liability pressure on the supply of obstetrician-gynecologists. *J Empirical Leg Stud* 2008;5(1):21-53.
70. Miller FG, **Mello MM**, Joffe S. Incidental findings in human research: what do investigators owe research participants? *J Law Med Ethics* 2008;36(2):271-279.
71. Barringer PJ, Studdert DM, Kachalia A, **Mello MM**. Administrative compensation of medical injuries: a hardy perennial blooms again. *J Health Polit Pol’y Law* 2008;33(4):725-760.
72. **Mello MM**, Rosenthal MB. Wellness programs and lifestyle discrimination—the legal limits. *N Engl J Med* 2008;359(2):192-199.
73. Siegal G, **Mello MM**, Studdert DM. Adjudicating severe birth injury claims in Florida and Virginia: The experience of a landmark experiment in personal injury compensation. *Am J Law Med* 2008;34:489-533.

74. Yang YT, **Mello MM**, Subramanian SV, Studdert DM. Relationship between malpractice litigation pressure and rates of cesarean section and vaginal birth after cesarean section. *Med Care* 2009;47(2):234-242.
75. **Mello MM**, Studdert DM, Brennan TA. Shifting terrain in the regulation of off-label promotion of pharmaceuticals. *N Engl J Med* 2009;360(15):1557-1566.
76. **Mello MM**. New York City's war on fat. *N Engl J Med* 2009;360(19):2015-2020.
77. Brennan TA, **Mello MM**. Incremental health care reform. *JAMA* 2009; 301(17):1814-1816.
78. Gallagher TH, Bell SK, Smith KM, **Mello MM**, McDonald TB. Disclosing harmful errors to patients: tackling three tough cases. *Chest* 2009;136:897-903.
79. **Mello MM**, Brennan TA. The role of medical liability reform in federal health reform. *N Engl J Med* 2009;361(1):1-3.
80. **Mello MM**, Gostin LO. A legal perspective on diabetes surveillance—privacy and the police power. *Milbank Q* 2009;87(3):575-580.
81. Bian J, Lipscomb J, **Mello MM**. Spillover effects of state mandated-benefit laws: the case of outpatient breast cancer surgery. *Inquiry* 2009;46:433-447.
82. **Mello MM**. Federal Trade Commission regulation of food advertising to children: possibilities for a reinigorated role. *J Health Polit Pol'y Law* 2010;35(2):227-276.
83. Kesselheim A, Studdert DM, **Mello MM**. Whistle-blowers' experiences in fraud litigation against pharmaceutical companies. *N Engl J Med* 2010;362(19):1832-1839.
84. Studdert DM, **Mello MM**, Brennan TA. Defensive medicine and tort reform—a wide view. *J Gen Intern Med* 2010;25(5):380-81.
85. **Mello MM**, Gallagher TH. Malpractice reform—opportunities for leadership by healthcare institutions and liability insurers. *N Engl J Med* 2010;362(15):1353-1356.
86. Winickoff J, Gottlieb M, **Mello MM**. Regulation of smoking in public housing. *N Engl J Med* 2010;362(24):2319-2325.
87. Burris S, Wagenaar AC, Swanson JW, Ibrahim JK, Wood J, **Mello MM**. Making the case for laws that improve health: a framework for public health law research. *Milbank Q* 2010;88(2):169-210.
88. **Mello MM**, Wolf LE. The Havasupai Indian tribe case—lessons for research involving stored biologic samples. *N Engl J Med* 2010;363(3):204-207.
89. Colgrove J, Abiola S, **Mello MM**. School mandates for HPV vaccination—public health law making amid political and scientific controversy. *N Engl J Med* 2010;363(8):785-791.

90. Carrier E, Reschovsky JD, **Mello MM**, Mayrell RC, Katz D. Physicians' fears of malpractice lawsuits are not assuaged by tort reforms. *Health Aff* 2010;29(9):1585-1592.
91. **Mello MM**, Chandra A, Gawande A, Studdert DM. National costs of the medical liability system. *Health Aff* 2010;29(9):1569-1577.
92. Mastroianni A, **Mello MM**, Sommer S, Hardy M, Gallagher TH. The flaws in state 'apology' and 'disclosure' laws dilute their intended impact on malpractice suits. *Health Aff* 2010;29(9):1611-1619.
93. Mangalmurti S, Murtagh L, **Mello MM**. Medical malpractice liability in the age of electronic health records. *N Engl J Med* 2010;362(21):2060-2067.
94. Studdert DM, Spittal MJ, **Mello MM**, O'Malley AJ, Stevenson DG. Relationship between quality of care and negligence litigation in nursing homes. *N Engl J Med* 2011;364:1243-50.
95. Kesselheim AS, **Mello MM**, Studdert DM. Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. *PLOS Med* 2011;8(4):e1000431.
96. Kachalia A, **Mello MM**. New directions in medical liability reform. *N Engl J Med* 2011;364(16):1564-1572.
97. Studdert DM, Kachalia AB, Salomon JA, **Mello MM**. Rationalizing noneconomic damages: a health-utilities approach. *Law & Contemp Prob* 2011;74:57-101.
98. Kesselheim A, Murtagh L, **Mello MM**. "Pay for delay" settlements of disputes over pharmaceutical patents. *N Engl J Med* 2011;365:1439-45.
99. Mangalmurti SS, Murtagh L, **Mello MM**. Medical malpractice in the military. *N Engl J Med* 2011;365(17):664-70.
100. **Mello MM**, Messing NA. Restrictions on the use of prescribing data for drug promotion. *N Engl J Med* 2011;365:1248-54.
101. Yang T, Studdert DS, Subramanian SV, **Mello MM**. Does tort law improve the health of newborns, or miscarry? A longitudinal analysis of the effect of liability pressure on birth outcomes. *J Empirical Leg Stud* 2012;9(2):217-45.
102. **Mello MM**, Abiola S, Colgrove J. Pharmaceutical companies' role in state vaccination policy making: the case of HPV vaccination. *Am J Pub Health* 2012;102(5):893-8.
103. Breckenridge A, **Mello M**, Psaty B. New horizons in pharmaceutical regulation. *Nature Drug Discov* 2012;11(7):501-2.
104. **Mello MM**, Goodman SN, Faden R. Ethical issues in studying drug safety—the Institute of Medicine's report and beyond. *N Engl J Med* 2012;367:959-64.

105. **Mello MM**, Cohen IG. The taxing power and the public's health. *N Engl J Med* 2012;367(19):1777-79.
106. **Mello MM**. Legal and policy approaches to the obesity epidemic. *Surg Obes & Related Dis* 2012;8(5):507-13.
107. Bell SK, Smulowitz PB, Woodward AC, **Mello MM**, Duva AM, Sands K. Disclosure, apology, and offer programs: stakeholders' views of barriers to and strategies for broad implementation. *Milbank Q* 2012;90(4):682-705.
108. **Mello MM**. Ejecting trans fat from New York City restaurants. *Nature Rev Endocrinol* 2012;8(11):633-5.
109. Murtagh L, Gallagher TH, Andrew P, **Mello MM**. Disclosure-and-resolution programs that include generous compensation offers may prompt a complex patient response. *Health Aff* 2012;31(12):2681-89.
110. Kesselheim AS, **Mello MM**, Avorn J. FDA regulation of off-label drug promotion under attack. *JAMA* 2013;309(5):445-6.
111. Abiola S, Colgrove J, **Mello MM**. The politics of HPV vaccination policy formation in the United States. *J Health Polit Pol'y Law* 2013;38(4):645-81.
112. Morain S, **Mello MM**. Survey finds public support for legal interventions directed at health behavior to fight noncommunicable disease. *Health Aff* 2013;32(3):486-96.
113. Kachalia A, **Mello MM**. Defensive medicine—legally necessary but ethically wrong? Inpatient stress testing for chest pain in low-risk patients. *JAMA Intern Med* 2013;173(12):1056-7.
114. Rosenthal MB, **Mello MM**. Sunlight as disinfectant—new rules on disclosure of industry payments to physicians. *New Engl J Med* 2013;368:2052-4.
115. Kachalia A, **Mello MM**. Breast cancer screening: conflicting guidelines and medicolegal risk. *JAMA* 2013;309(24):2555-6.
116. Morain S, Greene MF, **Mello MM**. A new era in noninvasive prenatal testing. *N Engl J Med* 2013;369(6):499-501.
117. Kesselheim AS, Cook-Deegan RM, Winickoff DE, **Mello MM**. Gene patenting—the Supreme Court finally speaks. *N Engl J Med* 2013(9);369:869-75.
118. Carrier E, Reschovsky J, Katz DA, **Mello MM**. High physician concern about malpractice risk predicts more aggressive diagnostic testing in office-based practice. *Health Aff* 2013;32(8):1383-91.
119. **Mello MM**, Parmet W. Editors' introduction. *J Health Polit Pol'y Law* 2013;38(4):629-43.

120. **Mello MM**, Wood J, Burris S, Wagenaar A, Ibrahim J, Swanson J. Critical opportunities for public health law: a call for action. *Am J Pub Health* 2013;103(11):1979-88.
121. **Mello MM**, Francer J, Wilenzick M, Teden P, Bierer BE, Barnes M. Preparing for responsible sharing of clinical trial data. *N Engl J Med* 2013;369(17):1651-8.
122. Gallagher TH, **Mello MM**, Levinson W, Wynia M, Sachdeva A, Sachdeva AK, Sulmasy SL, Truog R, Conway J, Mazor K, Lembitz A, Bell SK, Sokol-Hessner L, Shapiro J, Puopolo AL, Arnold R. Talking with patients and colleagues about other clinicians' errors. *N Engl J Med* 2013;369(18):1752-7.
123. Sage WM, Gallagher TH, Armstrong S, Cohn J, McDonald T, Gale J, Woodward A, **Mello MM**. How policy makers can smooth the way for communication-and-resolution programs. *Health Aff (Millwood)* 2014;33(1):11-19.
124. **Mello MM**, Boothman RC, McDonald T, Driver J, Lembitz A, Bouwmeester D, Dunlap B, Gallagher TH. Communication-and-resolution programs: the challenges and lessons learned from six early adopters. *Health Aff (Millwood)* 2014;33(1):20-29.
125. **Mello MM**, Senecal SK, Kuznetsov Y, Cohn JS. Implementing hospital-based communication-and-resolution programs: lessons learned in New York City. *Health Aff (Millwood)* 2014;33(1):30-38.
126. Winickoff JP, Gottlieb M, **Mello MM**. Tobacco 21: an idea whose time has come. *N Engl J Med* 2014;370(4):295-7.
127. **Mello MM**, Studdert DM. Making the case for health-enhancing laws after Bloomberg. *Hastings Cent Rep* 2014;44(1):8.
128. Kesselheim AS, **Mello MM**. Prospects for regulation of off-label drug promotion in an era of expanding commercial speech protection. *North Carolina Law Rev* 2014;92(5):1539-1604.
129. **Mello MM**, Cohen IG. Clinical trials and the right to remain silent. *JAMA Intern Med* 2014;174(9):1505-6.
130. **Mello MM**, Studdert DS, Kachalia A. The medical liability climate and prospects for reform. *JAMA* 2014;312(20):2146-55.
131. Haffajee R, Parmet W, **Mello MM**. What is a public health "emergency"? *N Engl J Med* 2014;371(11):986-8.
132. **Mello MM**, Merritt MW, Halpern SD. Supporting those who go to fight Ebola. *PLOS Med.* 2015;12(1):e1001781.
133. Morain SR, Joffe S, Campbell EG, **Mello MM**. Institutional oversight of faculty-industry consulting relationships in U.S. medical schools: a Delphi study. *J Law Med & Ethics* 2015;43(2):383-96.

134. MacCoun RJ, **Mello MM**. Half baked—the retail promotion of marijuana edibles. *N Engl J Med* 2015;372(11):989-91.
135. **Mello MM**, Catalano JN. Should malpractice settlements be secret? *JAMA Intern Med* 2015;175(7):1135-7.
136. Studdert DM, Flanders J, **Mello MM**. Searching for public health law’s sweet spot: the regulation of sugar-sweetened beverages. *PLOS Med* 2015;12(7):e1001848.
137. **Mello MM**, Studdert DM, Parmet WE. Shifting vaccination politics—the end of personal belief exemptions in California. *N Engl J Med* 2015. 2015;373:785-7.
138. Antman EM, Benjamin EJ, Harrington RA, House SR, Peterson ED, Bauman MA, et al. Acquisition, analysis and sharing of data in 2015 and beyond: a conference report from the American Heart Association Data Summit 2015. *J Am Heart Assoc* 2015;4(11): pii:e002810.
139. Kachalia A, **Mello MM**, Nallamotheu B, Studdert DM. Legal and policy interventions to improve patient safety. *Circulation* 2016;133(7):661-71.
140. Yang YT, Delamater PL, Leslie TF, **Mello MM**. Sociodemographic predictors of vaccination exemptions on the basis of personal belief in California. *Am J Pub Health* 2016;106(1):172-77.
141. Studdert DM, Bismark MM, **Mello MM**, Singh H, Spittal MJ. Prevalence and characteristics of physicians prone to medical malpractice claims. *N Engl J Med* 2016;374(4):354-62.
142. **Mello MM**, Livingston EH. Managing the risks of concurrent surgeries. *JAMA* 2016;315(15):1563-64.
143. Morain S, Winickoff JP, **Mello MM**. Have Tobacco 21 laws come of age? *N Engl J Med*. 2016;374(17):1601-04.
144. Bilimoria KY, Sohn MW, Chung JW, Minami C, Oh E, Pavey E, Holl J, Black BS, **Mello MM**, Bentrem DJ. Association between state medical malpractice environment and surgical quality and cost in the U.S. *Ann Surg* 2016;263(6):1126-32.
145. Gallagher TH, Farrell M, Karson H, Landreau T, Armstrong S, Maldon J, **Mello MM**, Cullen BF. Collaboration with regulators to support quality and accountability following medical errors: the CRP Certification Pilot. *Health Serv Res* 2016;51 Suppl 3:2569-82.
146. **Mello MM**, Greenberg Y, Senecal SK, Cohn JS. Case outcomes in a communication-and-resolution program in New York hospitals. *Health Serv Res* 2016;51 Suppl 3:2583-99.
147. Morain SR, Iezzoni LI, **Mello MM**, Park E, Metlay JP, Horner G, Campbell EG. When are primary care physicians untruthful with patients? A qualitative study. *AJOB Empirical Bioethics* 2017;8(1):32-39.

148. **Mello MM**, Armstrong S, Greenberg Y, Gallagher TH. Challenges of implementing a communication-and-resolution program where multiple organizations must cooperate. *Health Serv Res* 2016;51 Suppl 3:2550-68.
149. **Mello MM**, Studdert DM. Building a national surveillance system for malpractice claims. *Health Serv Res* 2016;51 Suppl 3:2642-2648.
150. Studdert DM, Donohue JJ, **Mello MM**. Testing the immunity of the firearm industry to tort litigation. *JAMA Intern Med* 2017;177(1):102-5.
151. Kachalia A, **Mello MM**, Studdert DM. Association of unsolicited patient observations with the quality of a surgeon's care. *JAMA Surg* 2017; 152(6):530.
152. Pham-Kanter G, **Mello MM**, Campbell EC, Lehmann LS, Carpenter DP. Public awareness of and contact with physicians who receive industry payments: a national survey. *J Gen Intern Med* 2017;32(7):767-74.
153. Moore J, **Mello MM**. Improving reconciliation following medical injury: a qualitative study of responses to patient safety incidents in New Zealand. *BMJ Qual Safety* 2017;26(1):788-98.
154. **Mello MM**, Kachalia A, Studdert DM. Medical liability—prospects for federal reform. *N Engl J Med* 2017;376(19):1806-8.
155. Bilimoria KY, Chung JW, Minami CA, Sohn MW, Pavey E, Holl J, **Mello MM**. Relationship between state malpractice environment and quality of health care in the United States. *Jt Comm J Qual Patient Saf* 2017;43(5):241-50.
156. **Mello MM**, Livingston EH. The evolving story of overlapping surgery. *JAMA* 2017;318(3):233-4.
157. Moore J, Bismark M, **Mello MM**. Patients' experiences with communication-and-resolution programs after medical injury. *JAMA Intern Med* 2017;177(11):1595-1603.
158. **Mello MM**, Kachalia A, Roche S, Van Niel M, Buchsbaum L, Dodson S, Folcarelli P, Benjamin EM, Sands KE. Outcomes in two Massachusetts hospital systems give reason for optimism about communication-and-resolution programs. *Health Aff* 2017;36(10):1795-1803.
159. Peters D, Keusch GT, Cooper J, Davis S, Lundgren J, **Mello MM**, Omatade O, Wabwire-Mangen F, McAdam KP. In search of global governance for research in epidemics. *Lancet* 2017;390(10103):1632-3.
160. Miller JE, Wilenzick M, Ritcey N, Ross JS, **Mello MM**. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies. *BMJ Open* 2017;7(12):e017917.
161. Haffajee RL, **Mello MM**. Drug companies' liability for the opioid epidemic. *N Engl J Med* 2017;377(24):2301-2305.



162. Morris AJ, **Mello MM**, Sanford JA, Green RB, Wald SH, Kadry B, Macario A. How should hospitals respond to surgeons' requests to schedule overlapping surgeries? *Neurosurgery* 2018;82(4):E91-E98.
163. Opel DJ, Sonne JA, **Mello MM**. Vaccination without litigation—addressing religious objections to hospital influenza vaccination mandates. *N Engl J Med* 2018;389(9):785-788.
164. **Mello MM**, Adler-Milstein J, Ding KL, Savage L. Legal barriers to the growth of health information exchange—boulders or pebbles? *Milbank Q* 2018;96(1):110-143.
165. Haffajee RL, **Mello MM**, Zhang F, Zaslavsky AM, Larochelle MR, Wharam JF. Four states with robust prescription drug monitoring programs reduced opioid dosages. *Health Aff (Millwood)* 2018;37(6):964-974.
166. **Mello MM**. What makes ensuring access to affordable prescription drugs the hardest problem in health policy? *Minn Law Rev* 2018;102(6):2273-2305.
167. London AJ, Omotade O, **Mello MM**, Keusch GT. Ethics of randomized trials in a public health emergency. *PLoS Negl Trop Dis* 2018;12(5): e0006313.  
<https://doi.org/10.1371/journal.pntd.0006313>.
168. **Mello MM**, Lieou V, Goodman S. Clinical trial participants' views of the risks and benefits of data sharing. *N Engl J Med* 2018;378(23):2202-2211.
169. Cohen IG, **Mello MM**. HIPAA and protecting health information in the 21<sup>st</sup> Century. *JAMA* 2018;320(3):231-232.
170. Haffajee RL, MacCoun R, **Mello MM**. Behind schedule—reconciling federal and state marijuana policy. *N Engl J Med* 2018;379(6):501-504.
171. **Mello MM**, Murtagh L, Joffe S, Taylor PL, Greenberg Y, Campbell EG. Beyond financial conflicts of interest—institutional oversight of faculty consulting agreements at schools of medicine and public health. *PLoS ONE* 2018;13(10):e0203179.
172. Gallagher TH, **Mello MM**, Bell SK, McDonald T, Sage WM, Thomas EJ. Can communication-and-resolution programs achieve their potential? Five key questions. *Health Aff (Millwood)* 2018;37(11):1845-1852.
173. Kachalia A, Sands KE, Van Niel M, Dodson S, Roche S, Novack V, Yishak-Sade M, Folcarelli P, Benjamin EM, Woodward AC, **Mello MM**. Effects of a communication-and-resolution program on hospitals' malpractice claims and costs. *Health Aff (Millwood)* 2018;37(11):1836-1844.
174. Dusetzina S, **Mello MM**. Disclosing prescription-drug prices in advertisements—legal and public health issues. *N Engl J Med* 2018;379(24):2290-3.

175. Kanter GP, Carpenter D, Lehmann LS, **Mello MM**. Effect of the public disclosure of industry payments information on patients: results from a population-based natural experiment. *BMJ Open* 2019;9(2):e024020. doi:10.1136/bmjopen-2018-024020.
176. Sun E, **Mello MM**, Rishel CA, Vaughn MT, Kheterpal S, Saager L, Fleisher LA, Damrose EJ, Kadry B, Jena AB; Multicenter Perioperative Outcomes Group (MPOG). Association of overlapping surgery with perioperative outcomes. *JAMA* 2019;321(8):762-72.
177. Haffajee RL, **Mello MM**, Zhang F, Busch A, Zaslavsky AM, Wharam JF. Association of federal mental health parity legislation with health care use and spending among high utilizers of services. *Med Care* 2019;57(4):245-255.
178. Studdert DM, Spittal MJ, Zhang Y, Wilkinson DS, Singh H, **Mello MM**. Changes in practice among physicians with malpractice claims. *N Engl J Med* 2019;380(13):1247-1255.
179. Kanter GP, Carpenter D, Lehmann LS, **Mello MM**. US nationwide disclosure of industry payments and public trust in physicians. *JAMA Network Open* 2019;2(4):e191947. doi:10.1001/jamanetworkopen.2019.1947.
180. Studdert DM, **Mello MM**. In from the cold? Law's evolving role in patient safety. *DePaul Law Rev* 2019;68(2):421-457.
181. Moore JS, **Mello MM**, Bismark M. "Poking the skunk": ethical and medio-legal concerns in research about patients' experiences of medical injury. *Bioethics* 2019;33(8):948-957.
182. Miller J, Ross JS, Wilenzick M, **Mello MM**. Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices. *BMJ* 2019;366:141247.
183. Sun E, **Mello MM**, Moshfegh J, Baker LC. Assessment of out-of-network billing for privately insured patients receiving care in in-network hospitals. *JAMA Intern Med* 2019;179(11):1543-50.
184. Cohen IG, **Mello MM**. Big Data, Big Tech, and protecting patient privacy. *JAMA* 2019;322(12):1141-1142.
185. Abiola SE, **Mello MM**. Multilevel legal approaches to obesity prevention: a conceptual and methodological toolkit. *PLoS ONE* 2019 Oct 1;14(10):e0220971. doi:10.1371/journal.pone.0220971.
186. **Mello MM**. Narrowing vaccination exemption laws: lessons from California and beyond. *Ann Intern Med* 2020;172(5):358-359.
187. **Mello MM**. Barriers to ensuring access to affordable drugs. *Annu Rev Pharmacol Toxicol* 2020;60:275-289.

188. **Mello MM**, Wolitz RE. Legal strategies for reining in “unconscionable” prices for prescription drugs. *Northwestern Law Rev* 2020;114(4):859-968.
189. **Mello MM**, Triantis G, Stanton R, Blumenkranz E, Studdert DM. Waiting for data: barriers to executing data use agreements. *Science* 2020;367(6474):150-152.
190. **Mello MM**, Roche S, Greenberg Y, Folcarelli PH, Van Niel M, Kachalia A. Ensuring successful implementation of communication-and-resolution programs. *BMJ Qual Safety* 2020;0:1-10.
191. **Mello MM**, Frakes MD, Blumenkranz E, Studdert DM. Malpractice liability and healthcare quality. *JAMA* 2020;323(4):352-366.
192. Sharfstein JM, Becker SJ, **Mello MM**. Diagnostic testing for the novel coronavirus. *JAMA* 2020;323(15):1437-1438.
193. **Mello MM**, Jagsi R. Standing up against sexual harassment and gender bias in medicine—a matter of professional ethics. *N Engl J Med* 2020;382(15):1385-1387. doi: 10.1056/NEJMp1915351.
194. Haffajee RL, **Mello MM**. Thinking globally, acting locally—the American response to Covid-19. *N Engl J Med* 2020;382(22):e75. doi: 10.1056/NEJMp2006740.
195. **Mello MM**, Persad G, White D. Respecting disability rights—toward improved crisis standards of care. *N Engl J Med* 2020;383(5):e26. doi: 10.1056/NEJMp2011997.
196. **Mello MM**, Wang CJ. Ethics and governance for digital disease surveillance. *Science* 2020;368(6494):951-954.
197. Hall MA, **Mello MM**, Studdert DM. The legal authority for states’ stay-at-home-orders. *N Engl J Med* 2020;383(5):e29. doi: 10.1056/NEJMp2019662.
198. **Mello MM**. Peering into hidden worlds: the past and future of legal epidemiology. *Temple Law Rev* 2020;92(4):837-849.
199. **Mello MM**, Silverman RD, Omer SB. Ensuring uptake of vaccines against the novel coronavirus. *N Engl J Med* 2020;383(14):1296-1299. doi: 10.1056/NEJMp2020926.
200. Studdert DM, Hall MA, **Mello MM**. Partitioning the curve—interstate travel restrictions during the Covid-19 pandemic. *N Engl J Med* 2020;383(13):e83. doi: 10.1056/NEJMp2024274.
201. **Mello MM**, Greene JA, Sharfstein JM. Attacks on public health officials during COVID-19. *JAMA* 2020;324(8):741-742. doi: 10.1001/jama.2020.14423.
202. Rafiei Y, **Mello MM**. The missing piece—COVID-19 testing and school reopening. *N Engl J Med* 2020;383(23):e126. doi: 10.1056/NEJMp2028209.

203. Goldhaber-Fiebert JD, Studdert DM, **Mello MM**. School reopenings: the broader context. *JAMA Health Forum* 2020 Oct 28. <https://jamanetwork.com/channels/health-forum/fullarticle/2772568>.
204. Fields AC, **Mello MM**, Kachalia A. Apology laws and malpractice liability—what have we learned? *BMJ Qual Safety* 2021;30(1):64-67. doi: 10.1136/bmjqs-2020-010955.
205. Pizzo P, Spiegel D, **Mello MM**. When physicians engage in practices that threaten the nation's health: a call to action. *JAMA* 2021;325(8):723-724. doi: 10.1001/jama.2021.0122.
206. Commissioners of the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. Announcing the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. *Lancet*. 2021 Feb 24:S0140-6736(21)00372-X. Epub ahead of print. doi: 10.1016/S0140-6736(21)00372-X.
207. Kachalia A, **Mello MM**. Supporting hospitals during a new wave of COVID-19. *J Hosp Med* 2021;16(5):311-312. doi: 10.12788/jhm.3610.
208. Liu S, **Mello MM**, Kesselheim AS. Prospects for enforcing prohibitions on off-label drug promotion after *United States v. Caronia*: an analysis of litigated cases. *J Health Polit Pol'y Law* 2021;46(3):487-504. doi: 10.1215/03616878-8893571.
209. Krass M, Henderson P, **Mello MM**, Studdert DM, Ho DE. How US law will evaluate artificial intelligence for Covid-19. *BMJ* 2021;372:n234. doi: 10.1136/bmj.n234.
210. Schulz-Moore JS, Bismark M, Jenkinson C, **Mello MM**. Assessing patients' experiences with medical injury reconciliation processes: item generation for a novel survey questionnaire. *Jt Comm J Qual Safety* 2021;47(6):376-384. doi: 10.1016/j.jcjq.2021.03.004.
211. Kramer DB, Opel DJ, Parasidis E, **Mello MM**. Choices within a crisis—individual preference among SARS-CoV-2 vaccines. *N Engl J Med* 2021. 384(17):e62. doi: 10.10056/NEJMp2102146.
212. **Mello MM**, Riley T. To address drug affordability, grab the low-hanging fruit. *JAMA* 2021;325(16):1599-1600. doi: 10.1001/jama.2021.4619.
213. Miller JE, **Mello MM**, Wallach JD, Grudbranson EM, Bohlig B, Ross JS, Gross C, Bach PB. Evaluation of drug trials in high-, middle-, and low-income countries and local commercial availability of newly approved drugs. *JAMA Netw Open* 2021;4(5):e217075. doi: 10.1001/jamanetworkopen.2021.7075.
214. Largent EA, Persad G, **Mello MM**, Wenner DM, Kramer DB, Edmonds BT, Peek M. Incorporating health equity into COVID reopening plans: policy experimentation in California. *Am J Pub Health* 2021;111(8):1481-1488. doi:10.2105/AJPH.2021.306263.
215. Kachalia A, **Mello MM**. The medical liability environment: is it really any worse for hospitalists? *J Hosp Med* 2021;16(7):446. doi:10.12788/jhm.3629.

216. Axson SA, **Mello MM**, Lincow D, Yang C, Gross CP, Ross J, Miller JE. Clinical trial transparency and data-sharing among bio-pharmaceutical companies and the role of company size, location, and product type: a cross-sectional descriptive analysis. *BMJ Open* 2021;11:e053248. doi:10.1136/bmjopen-2021-053248
217. Dusetzina SB, **Mello MM**. Drug pricing reform in 2021—going big or going bipartisan? *JAMA Health Forum* 2021;2(7):e212372. doi:10.1001/jamahealthforum.2021.2372.
218. **Mello MM**, Parmet WE. Public health law after Covid-19. *N Engl J Med* 2021;385(13):1153-5. doi: 10.1056/NEJMp2112193.
219. **Mello MM**, Studdert DM. The political and judicial battles over mask mandates for schools. *JAMA Health Forum* 2021;2(10):e214192. doi: 10.1001/jamahealthforum.2021.4192.
220. Sharfstein JM, Callaghan T, Carpiano RM, Sgaier SK, Brewer NT, Galvani AP, Lakshmanan R, McFadden SM, Reiss DR, Salmon DA, Hotez PJ; Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. Uncoupling vaccination from politics: a call to action. *Lancet*. 2021 Oct 2;398(10307):1211-1212. doi: 10.1016/S0140-6736(21)02099-7. Epub 2021 Sep 16. PMID: 34537104; PMCID: PMC8445735 - <https://pubmed.ncbi.nlm.nih.gov/34537104/>.
221. Omer SB, Benjamin RM, Brewer NT, Bутtenheim AM, Callaghan T, Caplan A, Carpiano RM, Clinton C, DiResta R, Elharake JA, Flowers LC, Galvani AP, Lakshmanan R, Maldonado YA, McFadden SM, **Mello MM**, Opel DJ, Reiss DR, Salmon DA, Schwartz JL, Sharfstein JM, Hotez PJ. Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. *Lancet*. 2021 Dec 11;398(10317):2186-2192. doi: 10.1016/S0140-6736(21)02507-1. Epub 2021 Nov 15. PMID: 34793741; PMCID: PMC8592561 - <https://pubmed.ncbi.nlm.nih.gov/34793741/>.
222. Salmon DA, Elharake JA, Brewer NT, Carpiano RM, DiResta R, Maldonado YA, Sgaier SK, Omer SB; Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. Vaccine verification in the COVID-19 world. *Lancet Reg Health Am* 2022 Feb;6:100161. doi: 10.1016/j.lana.2021.100161. Epub 2021 Dec 23. PMID: 34961857; PMCID: PMC8696017 - <https://pubmed.ncbi.nlm.nih.gov/34961857/>.
223. Brewer NT, Bутtenheim AM, Clinton C, **Mello MM**, Benjamin RM, Callaghan T, Caplan A, Carpiano RM, DiResta R, Elharake JA, Flowers LC, Galvani AP, Hotez PJ, Lakshmanan R, Maldonado YA, Omer SB, Salmon DA, Schwartz JL, Sharfstein JM, Opel DJ. Incentives for COVID-19 vaccination. *Lancet Reg Health Am* 2022;8:100205. <https://doi.org/10.1016/j.lana.2022.100205>
224. Jimenez RB, Johnson A, Horick N, Hlubocky F, Lei Y, Matsen C, Mayer EL, Collyar D, LeBlanc TW, Donelan K, **Mello MM**, Peppercorn J. Do you mind if I record? Perceptions and practice regarding patient requests to record clinic visits in oncology. *Cancer* 2022;128(2):275-83. doi: 10.1002/cncr.33910.

- 
225. **Mello MM**, Parmet WE. U.S. public health law—scope and emerging shifts. *N Engl J Med* 2022;386(9):805-8. doi:10.1056/NEJMp2200794.
  226. **Mello MM**. Vaccine misinformation and the First Amendment—the price of free speech. *JAMA Health Forum* 2022;3(3):e220732. doi:10.1001/jamahealthforum.2022.0732.
  227. Cullen MR, Baiocchi M, Chamberlain L, Chu I, Horwitz RI, **Mello M**, O’Hara A, Roos S. Population health science as a unifying foundation for translational clinical and public health research. *SSM Pop Health* 2022;18:101047. <https://doi.org/10.1016/j.ssmph.2022.101047>.
  228. Sun EC, **Mello MM**, Vaughn MT, Kheterpal S, Hawn MT, Dimick JB, Jena AB. Assessment of perioperative outcomes among surgeons who operated the night prior. *JAMA Intern Med.* 2022 May 23. doi: 10.1001/jamainternmed.2022.1563. Epub ahead of print.
  229. Spector-Bagdady K, **Mello MM**. Protecting the privacy of reproductive health information after the fall of *Roe v. Wade*. *JAMA Health Forum* 2022;3(6):e222656. doi:10.1001/jamahealthforum/2022.2656.
  230. **Mello MM**, Riley T, Sachs RE. The role of state attorneys general in improving prescription drug affordability. *Southern Cal Law Rev* 2022;95(3):595-662.
  231. **Mello MM**, Opel DJ, Benjamin RM, Callaghan T, DiResta R, Elharake JA, Flowers LA, Galvani AP, Salmon DA, Schwartz JL, Brewer NT, Bутtenheim AM, Carpiano RM, Clinton C, Hotez PJ, Lakshmanan R, Maldonado YA, Omer SB, Sharfstein JM, Caplan A. Effectiveness of vaccination mandates in improving uptake of COVID-19 vaccines in the United States. *Lancet* 2022;400(10351):535-538.
  232. **Mello MM**. Resuscitating abortion rights in emergency care. *JAMA Health Forum.* 2022;3(9):e223781. doi:10.1001/jamahealthforum.2022.3781.
  233. Opel DO, Brewer NT, Bутtenheim AM, Callaghan T, Carpiano RM, Clinton C, Elharake JA, Flowers LC, Galvani AP, Hotez PJ, Schwartz JL, Benjamin RM, Caplan A, DiResta R, Lakshmanan R, Maldonado YA, **Mello MM**, Parmet WE, Salmon DA, Sharfstein JM, Omer SB. The legacy of the COVID-19 pandemic for childhood vaccination in the USA. *Lancet* 2023;401(1037):75-78.
  234. Varma T, **Mello MM**, Ross JS, Gross CP, Miller JE. Varma T, Mello M, Ross JS, et al. Metrics, baseline scores, and a tool to improve sponsor performance on clinical trial diversity: retrospective cross sectional study. *BMJ Med* 2023;2:e000395. doi: 10.1136/bmjmed-2022-000395.
  235. **Mello MM**, O’Connell AJ. The fresh assault on insurance coverage mandates. *N Engl J Med* 2023;388(1):1-3. doi: 10.1056/NEJMp2213835.
  236. **Mello MM**, Lurie N, Sharfstein JM. The public health fixes that missed the omnibus. *JAMA Health Forum* 2023;4(2):e230263. doi:10.1001/jamahealthforum.2023.0263.

- 
237. Carpiano RM, Callaghan T, DiResta R, Brewer NT, Clinton C, Galvani AP, Lakshmanan R, Parmet WE, Omer SB, Bутtenheim AM, Benjamin RM, Caplan A, Elharake JA, Flowers LC, Maldonado YA., **Mello MM**, Opel DJ, Salmon DA, Schwartz JL, Sharfstein JM, Hotez PJ. Confronting the evolution and expansion of anti-vaccine activism in the United States in the COVID-19 era. *Lancet* 2023;401(10380):967-970.
238. Lee CD, Bradfield O, **Mello MM**, Beach MC. Discharging patients against medical advice. *N Engl J Med* 2023;388(13):1230-1232.
239. **Mello MM**, Gostin LO. Public health law modernization 2.0: rebalancing public health powers and individual liberty in the age of COVID-19. *Health Aff (Millwood)* 2023;42(3):318-327.
240. **Mello MM**, Meschke JS, Palmer GH. Mainstreaming wastewater surveillance for infectious diseases. *N Engl J Med* 2023;399(16):1441-1444.  
<https://www.nejm.org/doi/full/10.1056/NEJMp2301042>.
241. Reitsma MB, Dusetzina SB, Ballreich JM, Trujillo AJ, **Mello MM**. Examining opportunities to increase savings from Medicare price negotiations. *JAMA Intern Med* 2023;183(6):581-588. doi:10.1001/jamainternmed.2023.0763.
242. **Mello MM**, Guha N. ChatGPT and physicians' malpractice risk. *JAMA Health Forum* 2023;4(5):e231938. doi:10.1001/jamahealthforum.2023.1938.  
<https://jamanetwork.com/journals/jama-health-forum/fullarticle/2805334>.
243. Baugh CM, Glantz L, **Mello MM**. Decisions about college football during Covid-19: an ethical analysis. *J Law Med Ethics* 2023;51:104-118.
244. Langerman A, Hammack-Aviran C, Cohen IG, Agarwala AV, Cortez N, Feigenson NR, Fried G, Grandcharov T, Greenberg CC, **Mello MM**, Shuman AG. Navigating a path towards routine recording in the operating room. *Ann Surg* 2023;278(3):e474-e475. doi:10.1097/SLA.0000000000005906.
245. McCoy MS, Allen AL, Kopp K, **Mello MM**, Patil DJ, Ossorio P, Joffe S, Emanuel EJ. Ethical responsibilities for companies that process personal data. *Am J Bioethics* 2023;23(11):11-23. doi.org/10.1080/15265161.2023.2209535.
246. Shah NH, **Mello MM**. Discrepancies between clearance summaries and marketing materials of software-enabled medical devices cleared by the US Food and Drug Administration. *JAMA Netw Open* 2023;6(7):e2321753.  
doi:10.1001/jamanetworkopen.2023.21753.  
<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2806845>.
247. Dusetzina SB, Keating NL, Huskamp HA, **Mello MM**. Medicare's plan for drug-price negotiation—the importance of defining generic entry. *New Engl J Med* 2023;389:97-100. doi: 10.1056/NEJMp2304289.

248. Gostin LO, Reiss D, **Mello MM**. Vaccination mandates: an old public health tool faces new challenges. *JAMA* 2023;330(7):589-590. doi:10.1001/jama.2023.11059. <https://jamanetwork.com/journals/jama/fullarticle/2807811>.
249. **Mello MM**, Parmet WE. Accommodating religious objections to vaccination mandates—implications of *Groff v. DeJoy* for health care employers. *JAMA Health Forum* 2023;4(9):e233672.
250. **Mello MM**, Shah NH, Char DS. President Biden’s executive order on artificial intelligence—implications for healthcare organizations. *JAMA* 2024;331(7):17-18. <https://jamanetwork.com/journals/jama/fullarticle/2812613>.
251. **Mello MM**, Guha N. Understanding liability risk from using healthcare artificial intelligence tools. *N Engl J Med* 2024;390(3):271-278.
252. **Mello MM**, Jiang D, Platt E, Moran-McCabe K, Burris S. Sustaining a strong legal infrastructure for pandemic response: lessons not learned in the USA. *BMJ* 2024;384:e076269. <https://www.bmj.com/content/384/bmj-2023-076269>.
253. **Mello MM**, Rose S. Denial—artificial intelligence tools and health insurance coverage decisions. *JAMA Health Forum* 2024;5(3):e240622. <https://jamanetwork.com/journals/jama-health-forum/fullarticle/2816204>.
254. Arias J, Tyler AM, Beskow LM, Carillo MC, Dickinson S, Goldman J, Majumder M, **Mello MM**, Snyder HM, Yokoyama J. Data stewardship in FTLD research: investigator and research participant views. *Alzheimer’s Dement* 2024;20(4):2886-2893.
255. Lyerly AD, Faden RR, **Mello MM**. Beneath the sword of Damocles: moral obligations of physicians in a post-*Dobbs* landscape. *Hastings Ctr Rep* 2024;54(3):15-27.
256. **Mello MM**, Jiang DH, Parmet WE. Judicial decisions constraining public health powers during COVID-19: implications for public health policy making. *Health Aff (Millwood)* 2024;43(6):759-767. <https://www.healthaffairs.org/doi/10.1377/hlthaff.2024.00073>.
257. Callahan A, McElfresh D, Banda JM, Bunney G, Char D, Chen J, Corbin C, Dash D, Downing NL, Nallan S, Jain SS, Kotecha N, Masterson J, **Mello MM**, Morse K, Pandya A, Revri A, Sharma A, Sharp C, Thapa R, Wornow M, Youssef A, Pfeffer MA, Shah NH. Standing on FURM ground: a framework for deploying fair, useful, and reliable AI models in health care systems. *NEJM Catalyst* 2024;5(10). doi: 10.1056/CAT.24.0131. <https://catalyst.nejm.org/doi/full/10.1056/CAT.24.0131>.
258. **Mello MM**, Roberts JL. Antidiscrimination law meets artificial intelligence: health care providers’ and insurers’ new responsibilities. *JAMA Health Forum* 2024;5(8):e243397. <https://jamanetwork.com/journals/jama-health-forum/fullarticle/2823255>.
259. Fleisher LA, O’Connell AJ, **Mello MM**. Ramifications of the Supreme Court’s latest term for health regulation. *JAMA* 2024;332(16):1327-1329. <https://jamanetwork.com/journals/jama/fullarticle/2822931>.



260. White AA, Gallagher TH, Osinska PH, Kramer DB, Garrett KD, **Mello MM**. Ensuring safe practice by late career physicians: institutional policies and implementation experiences. *Ann Intern Med* 2024;177(12):1702-1710.
261. Jain SS, **Mello MM**, Shah NH. Avoiding patient financial toxicity from clinicians' use of AI. *N Engl J Med* 2024;391(13):1171-1173.  
<https://www.nejm.org/doi/full/10.1056/NEJMp2406135/>.
262. Reitsma MR, Dusetzina SB, Ballreich JB, Trujillo A, **Mello MM**. Estimated savings from extending prescription drug inflationary rebates to all commercial plans. *Health Aff (Millwood)* 2025;44(3):256-264.
263. **Mello MM**, Cohen IG. Regulation of health and health care artificial intelligence. *JAMA*. 2025;333(20):1769-1770. Associated *JAMA* podcast: <https://edhub.ama-assn.org/jn-learning/audio-player/18987040?resultClick=1>
264. **Mello MM**, Wang J. The hard road ahead for state public health departments. *JAMA Health Forum* 2025;6(3):e250817. <https://jamanetwork.com/journals/jama-health-forum/fullarticle/2831330>.
265. Miller JE, Pelletiers W, Varma T, Dilawari A, Fashoyin-Aje L, Gross CP, Kanapuru B, Lincoln C, **Mello M**, Patel T, Ramachandran R, Schwartz JL, Suttiratana SC, Ross JS. Representation of women, older adults, and racial and ethnic minoritized patients in pivotal trials for US Food and Drug Administration novel oncology therapeutic approvals, 2012-2021: bright spot trials and trends over time. *JCO Oncol Pract* 2025: OP2400563. [https://ascopubs.org/doi/10.1200/OP-24-00563?url\\_ver=Z39.88-2003&rfr\\_id=ori:rid:crossref.org&rfr\\_dat=cr\\_pub%20%20pubmed](https://ascopubs.org/doi/10.1200/OP-24-00563?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed).
266. McCoy MS, Gaines ME, Joffe S, Kanter GP, Largent EA, Lo B, Lynch HF, Whelan AM, **Mello MM**. A framework for assessing the permissibility of academic leaders' outside activities. *Milbank Q* 2025 Jun 4. Epub ahead of print. doi: 10.1111/1468-0009.70024. <https://onlinelibrary.wiley.com/doi/full/10.1111/1468-0009.70024>.
267. **Mello MM**, Char D, Xu S. Ethical obligations to inform patients about use of AI tools. *JAMA* 2025. Epub ahead of print, 21 Jul 2025.  
[https://jamanetwork.com/journals/jama/fullarticle/2836687?guestAccessKey=afa43aea-e704-4e02-b0cc-f21677d6ed9b&utm\\_source=For+The+Media&utm\\_medium=referral&utm\\_campaign=f+tm\\_links&utm\\_content=tfl&utm\\_term=072125](https://jamanetwork.com/journals/jama/fullarticle/2836687?guestAccessKey=afa43aea-e704-4e02-b0cc-f21677d6ed9b&utm_source=For+The+Media&utm_medium=referral&utm_campaign=f+tm_links&utm_content=tfl&utm_term=072125). Associated *JAMA* podcast: <https://podcasts.apple.com/us/podcast/navigating-transparency-and-trust-with-ai-in-health-care/id1772163310?i=1000722964046>

**OTHER:**

1. **Mello MM**. The role of clinical practice guidelines in malpractice litigation. *Forum* (Harvard Risk Management Foundation) 2000;20:1.

2. Burns JP, **Mello MM**, Studdert DM, Puopolo AL, Truog RD, Brennan TA. Results of a controlled clinical trial on care improvement for the critically ill [abstract and poster]. Academy for Health Services Research Annual Meeting 2002.
3. Studdert DM, **Mello MM**, Burns JP, Puopolo AL, Truog RD, Brennan TA. Conflicts in the care of patients with prolonged stay in the ICU: types, sources, and predictors [abstract and poster]. Academy for Health Services Research Annual Meeting 2002.
4. **Mello MM**, Brennan TA. Regulating health care quality: the case of patient safety. Commissioned paper for the Agency for Healthcare Research and Quality, 2002.
5. **Mello MM**. Institute of Medicine report 2002: "No fault" and other issues. *The Physician Insurer* 2003;First Quarter:14-17.
6. Hanscom RB, **Mello MM**, Powers RP, Sato L, Schaefer MA, Studdert DM. Legal liability and protection of patient safety data. Commissioned paper for the Institute of Medicine Committee on Patient Safety Data Standards, 2003.
7. **Mello MM**, Rosenthal MB, Neumann PJ. Liability for adverse events in direct-to-consumer advertising [letter]. *JAMA* 2003;289:2647.
8. **Mello MM**, Studdert DM, Brennan TA. Quality improvement efforts [letter]. *Health Aff* 2003;22(3):247-248.
9. Joffe S, **Mello MM**, Lee SJ. Advance care planning among patients undergoing hematopoietic stem cell transplantation [abstract and oral presentation]. American Society of Hematology Annual Meeting 2003.
10. **Mello MM**, Brennan TA. Tort law and medical quality: some lessons from the United States. In: J. Tingle, K. Wheat & C. Foster (eds.), *Regulating Health Care Quality: Legal & Professional Perspectives* (Oxford, UK: Elsevier Science, 2004).
11. Studdert DM, **Mello MM**, Brennan TA. Health policy review: medical malpractice. In: R.E. Anderson (ed.), *Medical Malpractice: A Physician's Sourcebook* (Totowa, NJ: Humana Press, 2004).
12. **Mello MM**, Studdert DM. The medical malpractice system: structure and performance. In: W.M. Sage & R. Kersh (eds.), *Medical Malpractice and the U.S. Health Care System: New Century, Different Issues* (Cambridge, UK: Cambridge University Press, 2006), 11-29.
13. Brennan TA, **Mello MM**, Studdert DM. Liability, patient safety, and defensive medicine: what does the future hold?. In: W.M. Sage & R. Kersh (eds.), *Medical Malpractice and the U.S. Health Care System: New Century, Different Issues* (Cambridge, UK: Cambridge University Press, 2006), 93-114.
14. **Mello MM**. Understanding malpractice insurance: a primer. Research Synthesis Report No. 8 (Princeton, NJ: The Robert Wood Johnson Foundation, 2006).

15. **Mello MM.** Medical malpractice: impact of the crisis and effect of state tort reforms. Research Synthesis Report No. 10 (Princeton, NJ: The Robert Wood Johnson Foundation, 2006). Available at <https://www.rwjf.org/en/library/research/2006/05/medical-malpractice-impact-of-crisis.html>.
16. **Mello M.** Book review: *Can We Say No? The Challenge of Health Care Rationing*. J Econ Lit 2006;44:1049-1054.
17. Moran P, Pomeranz J, **Mello MM.** Policies affecting access to sugar-sweetened beverages in schools: a legal and regulatory review. Report to the Robert Wood Johnson Foundation, 2006.
18. Bian J, Lipscomb J, **Mello MM.** Spillover effects of state mandated-benefit laws: the case of outpatient breast cancer surgery [abstract and oral presentation]. AcademyHealth Annual Meeting, 2007.
19. Studdert DM, **Mello MM,** Gawande A, Brennan TA. Disclosure: the authors respond [letter]. Health Aff 2007;26:904-05.
20. **Mello MM,** Chandra A. The cap doesn't fit. New York Times [op-ed], July 12, 2009.
21. **Mello MM.** Reform the medical liability system. New York Times [op-ed on nytimes.com], Nov. 14, 2010.
22. **Mello MM,** Kachalia A. Evaluation of options for medical malpractice system reform. Report to the Medicare Payment Advisory Commission. April 2010. Available at [http://www.medpac.gov/documents/Apr10\\_MedicalMalpractice\\_CONTRACTOR.pdf](http://www.medpac.gov/documents/Apr10_MedicalMalpractice_CONTRACTOR.pdf).
23. **Mello MM,** Kachalia A, Goodell S. Medical malpractice—update (Princeton, NJ: The Robert Wood Johnson Foundation, 2011). Available at <https://www.rwjf.org/en/library/research/2011/04/medical-malpractice-2011-update.html>.
24. **Mello MM,** Kachalia A, Studdert DM. Administrative compensation for medical injuries: lessons from three foreign systems (New York: Commonwealth Fund, 2011). Available at <http://www.commonwealthfund.org/Content/Publications/Issue-Briefs/2011/Jul/Medical-Injuries.aspx?omnicid=20>.
25. **Mello MM,** Kachalia A. Medical liability reform in Oregon: possibilities, costs, and benefits. Report to the Oregon Health Authority. January 2012.
26. **Mello MM,** Kachalia A. Administrative compensation of medical injuries: an analysis of the Florida approach. Report to the Oregon Health Authority. May 2012.
27. Burris S, Wagenaar AC, Swanson W, Ibrahim JK, Wood J, **Mello MM.** A framework for public health law research. In: A.C. Wagenaar and S. Burris (eds.), *Public Health Law Research: Theory and Methods* (San Francisco: Jossey-Bass, 2013).

28. **Mello MM.** When it comes to liability and patient safety, what's good for hospitals can be good for patients. *Huffington Post*, Feb. 13, 2014. Available at [http://www.huffingtonpost.com/michelle-mello/medical-errors\\_b\\_4769554.html](http://www.huffingtonpost.com/michelle-mello/medical-errors_b_4769554.html).
29. Kesselheim AS, **Mello MM.** Prospects for regulation of off-label drug promotion in an era of expanding commercial speech protection. In: H.F. Lynch and I.G. Cohen (eds), *FDA in the 21st Century: The Challenges of Regulating Drugs and New Technologies* (New York: Columbia University Press, 2015).
30. **Mello MM.** Should there be public access to data from clinical trials? *Human Capital Blog*, Robert Wood Johnson Foundation, June 16, 2014. Available at [http://www.rwjf.org/en/blogs/human-capital-blog/2014/06/should\\_there\\_be\\_publ.html](http://www.rwjf.org/en/blogs/human-capital-blog/2014/06/should_there_be_publ.html).
31. Engstrom N, Rabin RL, **Mello MM.** What Prop. 46 would fix. *Los Angeles Times* [op-ed], Oct. 28, 2014. Available at <http://www.latimes.com/opinion/op-ed/la-oe-engstrom-prop-20141029-story.html>.
32. **Mello MM.** The medical liability climate: the calm between storms is the time for reforms. *Bill of Health Blog*, Harvard Law School / Petrie Flom Center for Health Law Policy, Biotechnology, and Bioethics, Oct. 31, 2014. Available at <http://blogs.law.harvard.edu/billofhealth/2014/10/31/the-medical-liability-climate-the-calm-between-storms-is-the-time-for-reforms/>.
33. **Mello MM**, Studdert DM. When entertainment, reality, and ethics collide at the bedside. *Boston Globe* [op-ed], Jan. 16, 2015. Available at <http://www.bostonglobe.com/opinion/2015/01/16/when-entertainment-reality-and-ethics-collide-bedside/oyjfGs5gu2Dtgsr4ut4dtN/story.html>.
34. **Mello MM**, Studdert DM, Kachalia A. Medical liability and reporting malpractice payments—reply. *JAMA* 2015;313(10):1058.
35. **Mello MM**, Kachalia A. Medical malpractice: evidence on reform alternatives and claims involving elderly patients. Report to the Medicare Payment Advisory Commission. December 2016. [https://www.medpac.gov/wp-content/uploads/import\\_data/scrape\\_files/docs/default-source/reports/dec16\\_medicalmalpractice\\_medpac\\_contractor.pdf](https://www.medpac.gov/wp-content/uploads/import_data/scrape_files/docs/default-source/reports/dec16_medicalmalpractice_medpac_contractor.pdf).
36. **Mello MM.** Comment on two patients, two operating rooms, one surgeon—does the math add up? *Clin Orthop Relat Res.* 2016;474: 2097-2099.
37. Livingston EH, **Mello MM.** Length of stay after overlapping surgery—reply [letter]. *JAMA* 2017;318(21):2140-1.
38. **Mello MM**, Benjamin EM, Kachalia A. Avoiding malpractice suits: the authors reply [letter]. *Health Aff (Millwood)* 2018;37(4):676.
39. Moore J, **Mello MM.** What patients expect and deserve—reply [letter]. *JAMA Intern Med* 2018;178(4):578-579.

40. Engstrom FN, **Mello MM**. Litigation is critical to opioid response. *San Francisco Daily Journal*, Mar. 13, 2019:1.
41. **Mello MM**, Studdert DM, Nallamotheu BK, Kachalia A. The role of transparency in patient safety improvement. In: H.F. Lynch, I.G. Cohen, C. Schachar, and B.J. Evans (eds), *Transparency in Health and Health Care: Law and Ethics* (New York: Cambridge University Press, 2019).
42. Engstrom NF, **Mello MM**. The Oklahoma opioids verdict and ongoing litigation. *American Constitution Society Blog*, Aug. 29, 2019. <https://www.acslaw.org/expertforum/the-oklahoma-opioids-verdict-and-ongoing-litigation-qa/>.
43. Cohen IG, **Mello MM**. HIPAA in the era of data sharing—reply [letter]. *JAMA* 2020;323(5):477.
44. Kahn J, Johns Hopkins Project on Ethics and Governance of Digital Contact Tracing Technologies. *Digital Contact Tracing for Pandemic Response* (Baltimore: Johns Hopkins University Press, 2020). <https://muse.jhu.edu/book/75831/pdf>.
45. **Mello MM**. NASHP’s Proposal for Protecting Consumers from Prescription Drug Price Gouging [white paper]. July 6, 2020. <https://www.nashp.org/nashps-proposal-for-protecting-consumers-from-prescription-drug-price-gouging/>.
46. **Mello MM**, Dusetzina SB. NASHP’s Proposal for Imposing Penalties on Excessive Price Increases for Prescription Drugs [white paper]. August 14, 2020. <https://www.nashp.org/nashps-proposal-for-imposing-penalties-on-excessive-price-increases-for-prescription-drugs/>.
47. Miller JE, Ross JS, **Mello MM**. Far more transparency is needed for Covid-19 vaccine trials. *STAT*, Nov. 5, 2020. <https://www.statnews.com/2020/11/05/transparency-is-needed-for-covid-19-vaccine-trials/>
48. **Mello M**, Magnus D. The uncertain impact of accelerating science. *Sci Am* Dec. 3, 2020, <https://www.scientificamerican.com/custom-media/good-medicine/the-uncertain-impact-of-accelerating-science/>.
49. **Mello MM**, Cohen AB. Covid-19 pandemic priorities for President-Elect Biden. *Milbank Q Opinion*, Dec. 23, 2020. <https://doi.org/10.1599/mqop.2020.1223>.
50. **Mello MM**. My husband had a stroke after his COVID vaccine. We gave our kid his shot anyway. *San Francisco Chronicle*, Jul. 6, 2021. <https://www.sfchronicle.com/opinion/openforum/article/My-husband-had-a-stroke-after-his-COVID-vaccine-16294412.php>
51. **Mello MM**. Introduction. In: I.G. Cohen, A. Gluck, K. Krashel and C. Shachar (eds), *Covid-19 and the Law: Disruption, Impact and Legacy* In: H.F. Lynch, I.G. Cohen, C. Schachar, and B.J. Evans (eds) (New York: Cambridge University Press, 2023).

52. **Mello MM.** Modernizing public health emergency powers laws—again. Commonwealth Fund Blog, Mar. 30, 2023. [https://www.commonwealthfund.org/blog/2023/modernizing-public-health-emergency-powers-laws-again?utm\\_source=alert&utm\\_medium=email&utm\\_campaign=Improving+Health+Care+Quality](https://www.commonwealthfund.org/blog/2023/modernizing-public-health-emergency-powers-laws-again?utm_source=alert&utm_medium=email&utm_campaign=Improving+Health+Care+Quality).
53. **Mello MM.** I worried the COVID vaccine gave my husband a stroke. It took a year to find the truth. San Francisco Chronicle, May 22, 2023. <https://www.sfchronicle.com/opinion/openforum/article/covid-vaccine-stroke-health-18107346.php>.
54. Burris S, Wagenaar AC, Swanson W, Ibrahim JK, Wood J, **Mello MM.** A framework for public health law research. In: A.C. Wagenaar, R.L. Pacula, and S. Burris (eds.), *Legal Epidemiology: Theory and Methods* (2d edition) (Hoboken, New Jersey: John Wiley & Sons, 2023).
55. Yishak-Sade M, Kachalia A, Novack V, Mello MM. Reply to LeCraw, Montanera, and Mroz on hospitals' malpractice claims and costs. *Econ J Watch.* 2023;20(2):349-356.

#### **SELECTED PRESENTATIONS, LAST 3 YEARS:**

- 2023 “Tort Liability as a Compensation System for Injured Research Participants,” Invited presentation to NASEM Committee on Developing a Framework to Address Legal, Ethical, Regulatory, and Policy Issues for Research Specific to Pregnant and Lactating Persons (online).
- 2023 “Prescription Drug Costs and Access to Care,” Santa Clara University High Technology Law Journal Symposium on Diversity, Inclusion, and Wellness in the Tech and Law Fields, Santa Clara, CA.
- 2023 “Public Health Modernization 2.0: Rebalancing Public Health Powers and Individual Liberty in the Age of COVID-19,” Health Law Professors Conference, Baltimore, MD.
- 2023 “Publishing in High-Impact Medical Journals,” Health Law Professors Conference, Baltimore, MD.
- 2023 “Opportunities and Challenges in Implementing the Inflation Reduction Act,” Office of the Assistant Secretary for Planning and Evaluation (ASPE) Visiting Scholar Seminar (online).
- 2023 “Understanding Liability Risk from Health Care AI Tools,” Anesthesia Grand Rounds, Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA.
- 2023 “Understanding Liability Risk from Health Care AI Tools,” Research Colloquium, Stanford Center for Biomedical Informatics Research, Stanford University School of Medicine, Stanford, CA.

- 
- 2023 “Liability and Ethical Risk Assessment for Healthcare AI Tools,” AVIA Generative AI Collaborative Meeting (online).
- 2024 “Understanding Liability Risk from Health Care AI Tools,” Stanford Institute for Human-Centered Artificial Intelligence Seminar, Stanford University, Stanford, CA.
- 2024 “Investigating Ethical Concerns in AI Implementation: The Case of Nursing Notes Summarization via LLMs,” Coalition on Health AI Meeting (online).
- 2024 “Facilitating Responsible Governance of Healthcare AI Tools,” Testimony Before the Senate Committee on Finance, Washington, DC.
- 2024 “Institutional Governance of Health Care AI Tools,” American Board of Family Medicine EnAIBL Learning Collaborative Convening (online).
- 2024 “The Legal Infrastructure and COVID-19 Response,” Duke Global Health Institute Seminar on U.S. Pandemic Response: What Will It Take to Do Better?, Duke University, Durham, NC.
- 2024 “Stanford’s Approach to Ethical Assessment of AI Tools,” Coalition for Health AI Convening, Stanford, CA.
- 2024 “Looking to the Future: Where Do We Go From Here?” National Academies of Sciences, Engineering and Medicine Workshop on Optimizing Federal, State, and Local Response to Public Health Emergencies (online).
- 2024 “Judicial Decisions Constraining Public Health Powers During COVID-19: Implications For Public Health Policy Making,” Health Affairs Briefing on Reimagining Public Health (online).
- 2024 “Liability Risk From Using AI Tools in Patient Care,” Pediatrics Grand Rounds, Stanford University School of Medicine, Stanford, CA.
- 2024 “GenAI Governance at Stanford,” AVIA Generative AI Collaborative Meeting (online).
- 2024 “Liability Risk From Using AI Tools in Patient Care,” Virginia Health Medical Grand Rounds (online).
- 2024 “Liability and Ethics Issues Arising From Use of GenAI Tools in Healthcare,” Augmedix AI Council Meeting (online).
- 2024 “Transforming Healthcare Through Innovation,” Congressional Boot Camp on AI, Stanford HAI, Stanford, CA.
- 2024 “Understanding Liability Risk From Healthcare AI Tools,” Ethics Grand Rounds, UT Southwestern Medical Center (online).

- 
- 2024 “The Regulatory Landscape For AI in Healthcare,” JAMA Summit on Healthcare AI, Chicago, IL.
- 2024 “Bridging the Gap: Generative AI and Pediatrics,” AMIA 2024 Annual Symposium, San Francisco, CA.
- 2024 “AI Governance: Federal, State, and Private Roles,” National Conference of State Legislatures Health Innovation Task Force Meeting, Palo Alto, CA.
- 2025 “Augmented Intelligence – Balancing Interests and Identifying Appropriate State Guardrails,” American Medical Association State Advocacy Summit, Carlsbad, CA.
- 2025 “Understanding Liability Risk from AI Tools,” Medicine Grand Rounds, Methodist Dallas Medical Center (online).
- 2025 “Liability Risk from Using AI Tools in Pediatric Care,” Stanford Medicine Pediatric & Maternal Innovation Showcase, Stanford, CA.
- 2025 “Ethical Issues Arising from Implementation of AI Tools in Healthcare,” Stanford Center for Biomedical Ethics Seminar, Stanford, CA.
- 2025 “System-Level Ethical Issues Arising from AI Adoption,” AAMC-Manatt Digital Health and AI Learning Collaborative Retreat, Stanford, CA.
- 2025 “Understanding Liability Risk from Using Healthcare AI Tools,” Guy Carpenter Medical Professional Liability Forum, Cary, NC.
- 2025 “The Real Hurdle for AI Adoption: Liability,” STAT Breakthrough Summit West, San Francisco, CA.
- 2025 “Challenges in Resolving Claims for AI-Related Injuries to Patients,” Continuing Judicial Education Program on Telemedicine and Medical Malpractice: Legal Complexities and Evolving Standards of Care, Thomas R. Kline Center for Judicial Education (online).
- 2025 “Private Regulation to Ensure Safe Practice by Aging Physicians,” BioLawPalooza, Stanford Law School, Stanford, CA.
- 2025 “Generative AI in Healthcare: Challenges and Policy Implications,” Testimony before the California State Assembly Health and Privacy & Consumer Protection Committees, Sacramento, CA.
- 2025 “Stanford Ethics Work and Patient Engagement,” Coalition for Health AI Summer Convening, Stanford, CA.
- 2025 “Legal Liability in the Age of Medical AI,” AI in Medical Education Symposium, Stanford, CA.



- 
- 2025 “Insights From Listening to Patients,” Institute for Human-Centered Artificial Intelligence Health Policy Workshop, Stanford, CA
- 2025 “Moving Clinical AI Forward: A Policy Perspective,” Center for Artificial Intelligence in Medicine and Imaging Symposium, Stanford, CA.
- 2025 “Using Generative AI Tools in Clinical Practice: Benefits and Legal Risk Management,” ISMIE Risk Management Webinar (online).
- 2025 “Transforming Healthcare Through Innovation,” Congressional Boot Camp on AI, Stanford HAI, Stanford, CA.
- 2025 “Roundtable: AI in Health Technology,” Health Technology Innovation Congressional Bootcamp, Stanford Biodesign, Stanford, CA.
- 2025 “Regulatory and Policy Considerations in Healthcare AI Use,” Alignment Health Executive Education Session, Stanford Law School, Stanford, CA.